The prognosis following LEN–TACE treatment was linked to improved survival outcomes in patients with substantial tumor burden, including those with portal vein tumor thrombosis (PVTT), AFP levels of ≥400 ng/mL, three or more intrahepatic tumors, and a primary tumor size of ≥5 cm [137]. This evidence concerns the gene AFP and neoplasm.